$3.91
4.17% today
Nasdaq, Apr 29, 05:15 pm CET
ISIN
US60853G1067
Symbol
MOLN
Sector
Industry

Molecular Partners AG - ADR Stock price

$4.08
-0.48 10.59% 1M
-2.38 36.84% 6M
-0.67 14.07% YTD
+0.38 10.27% 1Y
-4.32 51.43% 3Y
-16.92 80.57% 5Y
-16.92 80.57% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
-0.12 2.84%
ISIN
US60853G1067
Symbol
MOLN
Sector
Industry

Key metrics

Market capitalization $150.45m
Enterprise Value $-11.75m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.18
EV/Sales (TTM) EV/Sales -2.09
P/S ratio (TTM) P/S ratio 26.72
P/B ratio (TTM) P/B ratio 0.96
Revenue growth (TTM) Revenue growth -27.77%
Revenue (TTM) Revenue $5.63m
EBIT (operating result TTM) EBIT $-69.50m
Free Cash Flow (TTM) Free Cash Flow $-63.68m
Cash position $164.90m
EPS (TTM) EPS $-1.81
P/E forward negative
P/S forward 266.28
EV/Sales forward negative
Short interest 0.22%
Show more

Is Molecular Partners AG - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Molecular Partners AG - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Molecular Partners AG - ADR forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Molecular Partners AG - ADR forecast:

Buy
71%
Hold
29%

Financial data from Molecular Partners AG - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5.63 5.63
28% 28%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
10% 10%
259%
- Research and Development Expense 55 55
2% 2%
980%
-67 -67
2% 2%
-1,187%
- Depreciation and Amortization 2.69 2.69
0% 0%
48%
EBIT (Operating Income) EBIT -69 -69
2% 2%
-1,234%
Net Profit -61 -61
11% 11%
-1,090%

In millions USD.

Don't miss a Thing! We will send you all news about Molecular Partners AG - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Molecular Partners AG - ADR Stock News

Neutral
GlobeNewsWire
4 days ago
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of three posters at the America...
Neutral
GlobeNewsWire
13 days ago
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that all motions proposed by the Board of Directors at the Annual General meeting were appr...
Neutral
GlobeNewsWire
about one month ago
Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer
More Molecular Partners AG - ADR News

Company Profile

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Head office Switzerland
CEO Patrick Amstutz
Employees 174
Founded 2004
Website www.molecularpartners.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today